AXSOME THERAPEUTICS, INC. Line of Credit Facility, Maximum Borrowing Capacity
AXSOME THERAPEUTICS, INC. (AXSM) had Line of Credit Facility, Maximum Borrowing Capacity of $350.00 million as of 2023-01-09, per its 10-Q filed 2025-05-05.
Financial Statements › Notes › Debt
us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity · last filed 2025-05-05
- 2023-01-09: Line of Credit Facility, Maximum Borrowing Capacity $350.00M.
| Period end | Line of Credit Facility, Maximum Borrowing Capacity |
|---|---|
| 2023-01-09 | $350.00M 10-Q · filed 2025-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |